A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population.
about
Pharmacokinetics of vancomycin in oncology egyptian paediatrics: a dosage adjustment trialPopulation pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulationCurrent recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.Validation of a pediatric population pharmacokinetic model for vancomycin.Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia.Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.Improved vancomycin dosing in children using area under the curve exposure.Lower vancomycin serum trough concentrations might not be the answer.Vancomycin: a review of population pharmacokinetic analyses.Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance?Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population.Vancomycin and gentamicin pharmacokinetic alterations in an adolescent amputee.Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 μg/ml in a pediatric intensive care unit.Vancomycin dosing in children and young adults: back to the drawing board.Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations
P2860
Q33555334-934299E6-175B-40CB-B434-D9336A2F2F87Q33797950-D25ACF6F-5B26-4F82-9F71-A2CFA7B82749Q34989352-CBACAFC9-D2BA-40AD-9128-D28A9CCB7A17Q35004264-DA57E415-4615-4360-9EC0-5EE59969E22EQ35607022-A2C8B543-A337-45AB-BA98-3005E9B1A7CEQ36077880-2E7454D0-F1BD-4955-979A-C35614E73B41Q36571794-9FA97CA3-718C-494C-B5EC-EECAAEFBFCF9Q36729959-B6E57BB7-2D45-474D-8074-72D35A5C4A85Q36784672-0718060E-F661-477F-B064-6137FB4E038FQ37608864-64629741-196D-441B-BA9B-1636C842A529Q37965578-C5096A2E-B363-41CE-A087-A1853B0B186EQ38258649-ED5DB552-1F2F-4183-8DDE-79F0BB934544Q38594191-79F0E6E5-E45C-4487-9879-B352FBEF21CDQ39197603-5936C715-05A1-460B-88BB-A30C988A2158Q39839904-337E4F6E-D843-44A9-A4F0-98383DADDA3CQ43984406-44AFB0D4-8F28-48BA-8AE1-9EAB917BC2B0Q45329118-F9AFD5B2-2D3F-40BE-9099-B28E25495022Q51165832-638F3609-EC0E-452E-9241-12AB99B797B8Q58699337-3AD4144D-1EED-4E6C-9B7E-78EC2CD3C1B4
P2860
A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
A population pharmacokinetic m ...... e value in a naive population.
@ast
A population pharmacokinetic m ...... e value in a naive population.
@en
type
label
A population pharmacokinetic m ...... e value in a naive population.
@ast
A population pharmacokinetic m ...... e value in a naive population.
@en
prefLabel
A population pharmacokinetic m ...... e value in a naive population.
@ast
A population pharmacokinetic m ...... e value in a naive population.
@en
P2093
P2860
P1476
A population pharmacokinetic m ...... e value in a naive population.
@en
P2093
P2860
P304
P356
10.1128/AAC.44.2.278-282.2000
P407
P577
2000-02-01T00:00:00Z